ArticleCancers2021
Prostate Cancer Mortality Associated with Aggregate Polymorphisms in Androgen-Regulating Genes: The Atherosclerosis Risk in the Communities (ARIC) Study.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.Carcinogenesis · 2024Pooled it
- Ameliorative effect of rufigallol on cisplatin-induced nephrotoxicity in rats: biochemical and histopathological evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Daphnetin alleviates cisplatin-induced acute kidney injury by inhibiting the HIF-1α signaling pathway.In vitro cellular & developmental biology. Animal · 2026Article
- Unraveling potent therapeutic potentials of tanshinones, lipophilic abietane diterpenes: a holistic literature review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Association between CYP17A1 and HSD3B1 gene polymorphisms and testosterone levels in Nigerian prostate cancer patients.Scientific reports · 2025Article
- Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.International urology and nephrology · 2025Review
- Advances in nephroprotection: the therapeutic role of selenium, silver, and gold nanoparticles in renal health.International urology and nephrology · 2025Review
- Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes.JCI insight · 2024Article
- Molecular Linkage between Immune System Disorders and Atherosclerosis.Current issues in molecular biology · 2023Review
- Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation.The Journal of clinical investigation · 2023Article
- BMX controls 3βHSD1 and sex steroid biosynthesis in cancer.The Journal of clinical investigation · 2023Article
- Expanding access to early phase trials: the CATCH-UP.2020 experience.JNCI cancer spectrum · 2023Article
- Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer.JNCI cancer spectrum · 2022Article
- Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer.Endocrine oncology (Bristol, England) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Genetic variations in androgen metabolism may influence prostate cancer (PC) prognosis. Clinical studies consistently linked PC prognosis with four single nucleotide polymorphisms (SNPs) in the critical androgen-regulating genes: 3-beta-hydroxysteroid dehydrogenase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.